HPV Vaccination and Screening with High-Performance Test: Brazilian Evidence

Brazil has a critical issue on women's health to solve: one woman dies every 90 minutes due to cervical cancer with a mean age of 45 years.[1] Considered eradicable cancer, there are two established strategies to control it: vaccination against HPV and periodic screening for detection of precancerous lesions. The Brazilian public health system offers both, free of charge, although this is not enough.

Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2021

• References

• 1 Ministério da Saúde. Instituto Nacional de Câncer Jose Alencar Gomes da Silva. [Estimate 2020: cancer incidence in Brazil] [Internet]. Rio de Janeiro: INCA; 2019 [cited 2021 Jun 22]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf. Portuguese
• 2 Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN. VACCINE study group. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine 2018; 36 (23) 3221-3230 DOI: 10.1016/j.vaccine.2018.04.080.
• 3 Falcaro M, Castañon A, Ndlela B. et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021;398(10316):2084–2092 10.1016/S0140-6736(21)02178-4 [ahead of print]
• 4 Drolet M, Bénard É, Pérez N, Brisson M. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394 (10197): 497-509 DOI: 10.1016/S0140-6736(19)30298-3.
• 5 Lei J, Ploner A, Elfström KM. et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383 (14) 1340-1348 DOI: 10.1056/NEJMoa1917338.
• 6 Ministério da Saúde. SI-PNI - Sistema de Informação do Programa Nacional de Imunizações. Coberturas vacinais – HPV Quadrivalente - Sexo feminino de 11 a 14 anos por idade e dose - Total Brasil – 2014 [Internet]. Brasília (DF): Ministério da Saúde; 2014 [cited 2020 Mar 12]. Available from: http://pni.datasus.gov.br/consulta_hpv_14_C01.php
• 7 Teixeira JC, Vianna MS, Vale DB. et al. School-based HPV vaccination: the challenges in a Brazilian initiative. Rev Bras Ginecol Obstet 2021; 43 (12) 923-931 DOI: 10.1055/s-0041-1740279.
• 8 Kreimer AR, Struyf F, Del Rosario-Raymundo MR. et al; Costa Rica Vaccine Trial Study Group Authors, PATRICIA Study Group Authors, HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators, GSK Vaccines Clinical Study Support Group. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015; 16 (07) 775-786 DOI: 10.1016/S1470-2045(15)00047-9.
• 9 Vale DB, Silva MT, Discacciati MG, Polegatto I, Teixeira JC, Zeferino LC. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS One 2021; 16 (05) e0251688 DOI: 10.1371/journal.pone.0251688.
• 10 Teixeira JC, Vale DB, Campos CS, Bragança JF, Discacciati MG, Zeferino LC. Organization of cervical cancer screening with DNA−HPV testing impact on early−stage cancer detection: a population−based demonstration study in a Brazilian city. Lancet Reg Health Am 2022; 5: 100084 DOI: 10.1016/j.lana.2021.100084.